SCHEMBL3493344

SCHEMBL3493344

CN1C(C)(C)CC(Nc2nc(Nc3cc4c(cc3Cl)OCO4)ncc2F)CC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.47
ULK1 O75385 3/20 0.40
LRRK2 Q5S007 2/20 0.40
CYP3A4 P08684 1/20 0.40
SCN9A Q15858 1/20 0.40
SYK P43405 2/20 0.39
BRD4 O60885 1/20 0.39
BCL6 P41182 2/20 0.38
AURKA O14965 2/20 0.37
AURKB Q96GD4 1/20 0.37
CSNK2A2 P19784 2/20 0.36
CSNK2A1 P68400 2/20 0.36
CCND1 P24385 1/20 0.35
CDK6 Q00534 1/20 0.35
STK17B O94768 1/20 0.35
STK17A Q9UEE5 1/20 0.35
BMX P51813 1/20 0.35
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496422 0.94 PRKCQ (0.47) PRKCQULK1LRRK2CYP3A4SCN9A
SCHEMBL3493315 0.84 PRKCQ (0.54) PRKCQLRRK2BRD4BCL6AURKA
SCHEMBL3494055 0.84 ULK1 (0.56) PRKCQULK1SYKBRD4STK17B
SCHEMBL3495124 0.81 PRKCQ (0.51) PRKCQULK1LRRK2SYKAURKA
SCHEMBL3494261 0.81 PRKCQ (0.49) PRKCQULK1LRRK2CYP3A4SCN9A
SCHEMBL3496512 0.79 PRKCQ (0.59) PRKCQSYKBCL6AURKAAURKB
SCHEMBL3497243 0.79 PRKCQ (0.47) PRKCQULK1LRRK2CYP3A4SCN9A
SCHEMBL3495845 0.79 PRKCQ (0.56) PRKCQSYKBRD4BCL6AURKA
SCHEMBL3496315 0.79 PRKCQ (0.56) PRKCQULK1SYKBCL6STK17B
SCHEMBL3494882 0.78 SYK (0.62) PRKCQULK1SYKBRD4BMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885ULK1 832/4885LRRK2 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.